A survey of UK patients receiving the drug diazoxide, revealed 40 pati
ents with insulinoma on this treatment. Mean age (+/-SD) was 67+/-18 y
ears, and 74% were female. Duration of treatment was 7+/-6 years (rang
e 1-22). Most (55%) patients were treated with diazoxide because of tu
mour non-localisation (including failed previous surgery). Metastatic
disease (20%) and poor surgical risk (10%) were other indications. Sid
e-effects (notably fluid retention and hirsutism) were common (47%) bu
t not troublesome. Treatment was highly effective - 59% were symptom f
ree and 38% had only occasional symptoms. Only one patient had frequen
t hypoglycaemia despite treatment. We conclude that diazoxide is effec
tive in the management of insulinoma. Side-effects are common but not
problematic. Treatment should be considered for all patients not cured
by surgery, or unsuitable for surgical treatment.